Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and tailor decisions to individual patient circumstances, considering all available clinical data and the latest evidence.

---

Celiac Disease

Overview

• Definition: Celiac disease (CD) is a chronic, immune-mediated enteropathy triggered by the ingestion of gluten (a protein found in wheat, barley, and rye) in genetically predisposed individuals. It is characterized by small intestinal mucosal damage (villous atrophy) leading to nutrient malabsorption, and a wide spectrum of clinical manifestations.
• Epidemiology:
  • Prevalence: Global prevalence is estimated to be approximately 1% in the general population, although it varies geographically. It is significantly underdiagnosed.
  • Incidence: Increasing incidence reported worldwide.
  • Demographics: Affects all ages, from infancy to older adulthood, though diagnosis often occurs in childhood or middle age. There is a slight female predominance (ratio 2:1). First-degree relatives of individuals with CD have a 10-15% increased risk.
• Classification:
  • Classical Celiac Disease: Characterized by prominent signs and symptoms of malabsorption (e.g., chronic diarrhea, abdominal distension, weight loss, growth faltering in children).
  • Atypical Celiac Disease: More common, presenting with extra-intestinal symptoms or non-specific gastrointestinal symptoms without overt malabsorption (e.g., iron deficiency anemia, fatigue, osteoporosis, elevated liver enzymes, neurological symptoms, dental enamel defects).
  • Silent Celiac Disease: Individuals have positive serology and villous atrophy on biopsy but are asymptomatic. Diagnosed through screening of high-risk groups (e.g., first-degree relatives).
  • Potential Celiac Disease: Individuals with positive celiac serology but normal small intestinal mucosa on biopsy, who may or may not develop villous atrophy over time.
  • Refractory Celiac Disease (RCD): Persistent or recurrent malabsorptive symptoms and villous atrophy despite strict adherence to a gluten-free diet (GFD) for at least 6-12 months, after exclusion of other causes. RCD is further classified into Type I (polyclonal T-cell infiltrate) and Type II (abnormal, monoclonal intraepithelial lymphocyte population with poor prognosis).

Pathophysiology

• Mechanism: Celiac disease is an autoimmune disorder driven by an immune response to gluten.
  1. Genetic Predisposition: Over 95% of CD patients carry HLA-DQ2 (DQA105:01, DQB102:01) or HLA-DQ8 (DQA103:01, DQB103:02) haplotypes. These molecules present gluten peptides to T cells.
  2. Gluten Ingestion: Gliadin (a component of gluten) peptides, particularly those resistant to full digestion, cross the intestinal epithelial barrier.
  3. Deamidation by Tissue Transglutaminase (tTG): Within the lamina propria, the enzyme tTG deamidates gliadin peptides, increasing their negative charge and enhancing their binding affinity to HLA-DQ2/DQ8 molecules.
  4. T-cell Activation: Deamidated gliadin peptides are presented by antigen-presenting cells (APCs) to CD4+ T helper cells. This activates T cells, leading to a Th1-mediated immune response with release of pro-inflammatory cytokines (e.g., interferon-gamma, IL-15).
  5. B-cell Activation and Autoantibody Production: Activated T cells also help activate B cells, leading to the production of autoantibodies, particularly anti-tTG, anti-endomysial (EMA), and anti-deamidated gliadin peptide (DGP) antibodies.
  6. Mucosal Damage: The chronic inflammatory response damages the small intestinal lining, leading to characteristic pathological changes: villous atrophy (flattening of the villi), crypt hyperplasia (elongation of the crypts), and increased intraepithelial lymphocytes (IELs). This damage impairs nutrient absorption.
• Risk Factors:
  • Genetic: Presence of HLA-DQ2 or HLA-DQ8 haplotypes.
  • Family History: First-degree relatives (parents, siblings, children) of CD patients.
  • Autoimmune Diseases: Type 1 Diabetes Mellitus (T1DM), autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease), Addison's disease, autoimmune liver disease, Sjögren's syndrome.
  • Other Conditions: Down syndrome, Turner syndrome, Williams syndrome, Selective IgA deficiency (requires specific diagnostic approach), microscopic colitis.
  • Environmental: Early childhood infections (e.g., rotavirus), although this is less definitively established.
• Protective Factors:
  • No definitively proven protective factors. Early theories regarding breastfeeding duration and timing of gluten introduction have largely been disproven or show inconsistent evidence.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Chronic or recurrent diarrhea (often steatorrhea – fatty, foul-smelling stools).
  • Abdominal pain and distension.
  • Weight loss or poor weight gain (in children).
  • Fatigue.
  • Anemia (most commonly iron deficiency anemia, often refractory to oral iron supplementation).
• Early Signs:
  • Vague gastrointestinal discomfort.
  • Mild fatigue.
  • Occasional constipation or diarrhea.
  • Iron deficiency anemia without obvious GI symptoms.
• Advanced Signs:
  • Severe malabsorption leading to:
    • Muscle wasting and cachexia.
    • Peripheral edema (due to hypoalbuminemia).
    • Osteoporosis or osteopenia, increased fracture risk.
    • Neurological symptoms (peripheral neuropathy, ataxia, epilepsy with cerebral calcifications, "brain fog").
    • Dermatitis herpetiformis (intensely pruritic, blistering skin rash, typically on extensor surfaces).
    • Bleeding tendencies (due to vitamin K deficiency).
    • Glossitis, aphthous stomatitis (mouth ulcers).
• Atypical Presentations: Increasingly common and challenging to diagnose.
  • Chronic fatigue.
  • Iron deficiency anemia (most common atypical presentation).
  • Short stature or delayed puberty in children.
  • Recurrent aphthous stomatitis.
  • Elevated liver transaminases of unknown origin.
  • Infertility or recurrent miscarriages.
  • Dental enamel defects.
  • Unexplained neurological symptoms.
  • Arthralgia or arthritis.

Physical Examination

• Inspection:
  • Pallor (suggestive of anemia).
  • Signs of muscle wasting, subcutaneous fat loss.
  • Abdominal distension.
  • Edema (especially peripheral, indicative of hypoalbuminemia).
  • Presence of dermatitis herpetiformis (vesiculobullous rash, often excoriated).
  • Cheilosis, glossitis, angular stomatitis (vitamin deficiencies).
  • Dental enamel hypoplasia (pitting, grooves, discoloration in children).
• Palpation:
  • Abdominal tenderness, especially in the periumbilical region.
  • Abdominal distension (tympanitic).
• Special Tests: No specific maneuvers, but general assessment for signs of nutrient deficiencies (e.g., easy bruising for vitamin K, bone tenderness for osteomalacia).

Diagnostic Approach

History Taking

• Key Questions:
  • GI Symptoms: Nature, frequency, duration of diarrhea (steatorrhea?), abdominal pain, bloating, nausea, vomiting, constipation.
  • Extra-intestinal Symptoms: Fatigue, weight loss, anemia history, bone pain/fractures, skin rashes, neurological symptoms, oral ulcers, dental issues, reproductive history (infertility, miscarriages).
  • Dietary History: Current and recent gluten intake. Crucially, the patient must be consuming gluten-containing foods regularly for at least 4-6 weeks (ideally equivalent to 1-2 slices of bread daily) prior to serological testing and biopsy for accurate results.
  • Family History: History of CD or autoimmune diseases in first-degree relatives.
  • Past Medical History: History of other autoimmune conditions (T1DM, thyroid disease), IgA deficiency, Down/Turner/Williams syndromes.
  • Medications/Supplements: Rule out other causes of symptoms.
• Red Flags:
  • Unexplained iron deficiency anemia.
  • Chronic diarrhea (especially if steatorrhea).
  • Unexplained weight loss or growth faltering in children.
  • New-onset autoimmune disease in adults.
  • Dermatitis herpetiformis.

Laboratory Tests

• First-Line (Must be on a gluten-containing diet):
  • Total Serum IgA: Essential to rule out selective IgA deficiency, which is more common in CD patients and can lead to false-negative IgA-based antibody tests.
  • IgA Anti-tissue Transglutaminase (tTG-IgA) antibody: This is the primary screening test, highly sensitive (>95%) and specific (>95%).
  • If IgA deficient: Order IgG Anti-tissue Transglutaminase (tTG-IgG) or IgG Deamidated Gliadin Peptide (DGP-IgG) antibodies. DGP-IgG can also be useful in children under 2 years old and in cases where tTG-IgA is equivocal.
  • EMA-IgA (endomysial antibody-IgA): Highly specific (>99%) but operator-dependent (immunofluorescence), often used as a confirmatory serologic test, especially if tTG-IgA is positive.
• Confirmatory (Gold standard for diagnosis in adults):
  • Upper Endoscopy with Small Intestinal Biopsy (Esophagogastroduodenoscopy - EGD):
    • Procedure: At least four biopsies should be taken from the distal duodenum (beyond the duodenal bulb) and at least two from the duodenal bulb.
    • Histopathology: Biopsies are assessed for characteristic changes using the Marsh-Oberhuber classification system:
      • Marsh 0: Normal mucosa
      • Marsh 1: Increased intraepithelial lymphocytes (IELs) (>25 IELs/100 enterocytes)
      • Marsh 2: Increased IELs and crypt hyperplasia
      • Marsh 3: Increased IELs, crypt hyperplasia, and villous atrophy (further subdivided into Marsh 3a: partial villous atrophy, 3b: subtotal villous atrophy, 3c: total villous atrophy). Marsh 3 is diagnostic for CD.
  • Genetic Testing (HLA-DQ2/DQ8):
    • Utility: Not diagnostic for CD, as approximately 25-30% of the general population carries these genes. However, a negative result virtually excludes CD (Negative Predictive Value >99%), making it useful in specific scenarios (e.g., ruling out CD in potential cases, clarifying diagnosis in difficult cases, screening first-degree relatives).
• Monitoring:
  • Follow-up Serology: IgA tTG (or IgG tTG/DGP if IgA deficient) should be monitored, typically 6-12 months after starting GFD, and then annually. A decreasing trend and eventual normalization indicates adherence to GFD and mucosal healing.
  • Nutritional Status:
    • Complete Blood Count (CBC)
    • Ferritin, serum iron, TIBC (Total Iron-Binding Capacity)
    • Folate, Vitamin B12
    • Vitamin D, Calcium, Phosphate
    • Liver enzymes (ALT, AST, ALP)
  • Bone Mineral Density: Dual-energy X-ray absorptiometry (DEXA) scan at diagnosis and follow-up as indicated (e.g., every 1-3 years if osteopenia/osteoporosis, or baseline and 5 years if normal).

Imaging

• Recommended:
  • DEXA scan: To assess bone mineral density, especially important at diagnosis due to increased risk of osteoporosis/osteopenia.
• Advanced (Not for initial diagnosis, but for complications or refractory cases):
  • CT Enterography or MR Enterography: Can be used to evaluate the small bowel for complications of CD, such as strictures, ulcerations, or suspicion of malignancy (e.g., lymphoma, adenocarcinoma) in patients with refractory disease.
  • Capsule Endoscopy: May be used in refractory CD to visualize the entire small bowel for subtle lesions, ulcerations, or polyps, particularly when malignancy is suspected but not seen on routine endoscopy.

Management

Acute Management

• Immediate:
  • For severely symptomatic patients with significant malabsorption or dehydration: Fluid and electrolyte repletion, correction of severe deficiencies (e.g., IV iron, vitamin K).
• Stabilization:
  • Address severe nutritional deficiencies (e.g., parenteral nutrition if oral intake is insufficient, blood transfusion for severe anemia).
  • Manage symptomatic manifestations (e.g., anti-diarrheals for severe diarrhea, although the primary treatment is GFD).
• Emergency: Rarely required. May include management of bowel obstruction or perforation, though these are extremely rare complications of severe, untreated CD.

Chronic Management

• Pharmacological:
  • Strict, Lifelong Gluten-Free Diet (GFD): This is the cornerstone and only established treatment. No specific medications exist to 'cure' CD.
  • Nutritional Supplementation:
    • Iron: Oral iron supplementation for iron deficiency anemia.
    • Folate, Vitamin B12: For megaloblastic anemia.
    • Vitamin D, Calcium: For bone health, especially if osteopenia/osteoporosis is present. Typical dosages: Vitamin D 800-2000 IU/day, Calcium 1000-1200 mg/day (elemental calcium).
    • Multivitamins: May be beneficial, especially early in treatment, until mucosal healing is complete.
  • Corticosteroids:
    • Prednisone: Used in refractory celiac disease (RCD) to induce remission, particularly in Type I RCD. Typical dose 20-40 mg/day, tapered over weeks to months.
    • Budesonide: Less systemic absorption, may be considered for RCD.
  • Immunosuppressants: For refractory celiac disease (Type I or Type II).
    • Azathioprine or 6-mercaptopurine: Often used for long-term maintenance in RCD-I after steroid induction.
    • Cyclosporine, Tacrolimus, Biologics (e.g., anti-TNF agents like infliximab): May be considered for severe RCD, especially Type II, often in a specialized center.
• Non-pharmacological:
  • Dietary Counseling: Mandatory referral to a registered dietitian with expertise in CD. This is critical for successful GFD adherence. Education includes:
    • Identifying gluten-containing foods (wheat, barley, rye, and derivatives).
    • Recognizing hidden gluten in processed foods, medications, supplements.
    • Preventing cross-contamination in the kitchen and food preparation.
    • Understanding food labeling ("gluten-free" regulations vary by country, generally <20 ppm gluten).
  • Patient Education: Comprehensive understanding of CD, its long-term nature, and the importance of lifelong adherence.
  • Support Groups: Can provide valuable peer support and practical advice.
• Monitoring:
  • Clinical Follow-up: Regular visits with a gastroenterologist (initially 3-6 months, then annually once stable). Assess symptom resolution, adherence to GFD, and identify new issues.
  • Serology: Follow-up IgA tTG (or IgG tTG/DGP) levels to monitor GFD adherence and mucosal healing. Normalization of serology typically occurs within 6-12 months for children and 12-24 months for adults.
  • Nutritional Assessment: Regular monitoring of CBC, ferritin, vitamin D, calcium, and liver enzymes.
  • Bone Density: Repeat DEXA scan (e.g., 1-5 years post-diagnosis, depending on initial results and risk factors).
  • Repeat Endoscopy/Biopsy: Not routinely recommended for confirming mucosal healing in asymptomatic patients, but considered if symptoms persist despite strict GFD, serology doesn't normalize, or if there's suspicion of complications (e.g., refractory CD, malignancy).

Treatment Algorithms

• First-Line:
  1. Strict, lifelong Gluten-Free Diet (GFD).
  2. Referral to a specialized registered dietitian.
  3. Correction of nutritional deficiencies with appropriate supplementation.
  4. Initial clinical and serological monitoring (3-6 months, then annually).
• Second-Line (For persistent symptoms or non-normalization of serology despite GFD):
  1. Re-evaluation of diagnosis: Confirm initial biopsies were diagnostic, consider alternative causes of symptoms.
  2. Assessment of GFD adherence: Detailed dietary interview with a dietitian, check for hidden gluten or accidental exposure.
  3. Rule out concomitant conditions: Lactose intolerance, SIBO (Small Intestinal Bacterial Overgrowth), microscopic colitis, pancreatic exocrine insufficiency, Irritable Bowel Syndrome (IBS).
  4. Consider repeat endoscopy with biopsies: To assess mucosal healing and rule out refractory CD or complications.
• Refractory Cases:
  1. Referral to a specialized celiac center.
  2. Confirm refractory CD Type I vs. Type II: Requires specialized pathological review of biopsies with T-cell receptor gene rearrangement studies.
  3. For Refractory Celiac Disease Type I: Corticosteroids (e.g., prednisone 20-40 mg/day tapering dose) to induce remission, followed by immunosuppressants (e.g., azathioprine 2-2.5 mg/kg/day, or 6-mercaptopurine) for maintenance.
  4. For Refractory Celiac Disease Type II: Prognosis is poor, with high risk of progression to enteropathy-associated T-cell lymphoma (EATL). Management is complex, often involves corticosteroids, and may include stronger immunosuppressants (e.g., cyclosporine, tacrolimus) or biologics (e.g., infliximab). Hematopoietic stem cell transplantation may be considered in selected cases. Close surveillance for EATL is crucial.

Complications

• Common:
  • Nutritional Deficiencies: Iron deficiency anemia (most common), folate deficiency, B12 deficiency, vitamin D deficiency, calcium deficiency.
  • Osteopenia/Osteoporosis: Due to impaired calcium and vitamin D absorption. Increased fracture risk.
  • Functional GI Symptoms: Persistence of IBS-like symptoms in some patients despite GFD.
  • Lactose Intolerance: Transient in many, improves with mucosal healing.
• Serious:
  • Refractory Celiac Disease (RCD): Persistent symptoms and villous atrophy despite strict GFD. Higher risk of malignancy in Type II.
  • Enteropathy-Associated T-cell Lymphoma (EATL): Rare but aggressive non-Hodgkin lymphoma of the small intestine, primarily seen in long-standing, untreated, or refractory CD. Mortality rate is high.
  • Small Bowel Adenocarcinoma: Rare, but increased risk compared to general population.
  • Ulcerative Jejunoileitis: Non-specific ulcers in the jejunum/ileum, often seen with RCD.
  • Hyposplenism: Impaired splenic function, leading to increased susceptibility to encapsulated bacterial infections.
• Long-term:
  • Increased Risk of Other Autoimmune Diseases: Especially Type 1 Diabetes, autoimmune thyroid disease, and autoimmune liver diseases.
  • Increased Fracture Risk: Even after GFD.
  • Chronic Fatigue and Reduced Quality of Life: Even with good GFD adherence in some individuals.

Prognosis

• Factors:
  • Adherence to GFD: Strict, lifelong GFD is associated with excellent prognosis and reduction in complications.
  • Age at Diagnosis: Earlier diagnosis and GFD initiation generally lead to better outcomes.
  • Severity of Mucosal Damage: More severe atrophy at diagnosis may take longer to heal.
  • Presence of Complications: Development of RCD or malignancy significantly worsens prognosis.
• Survival:
  • With strict adherence to a GFD, mortality rates for individuals with CD are similar to the general population.
  • Untreated CD or refractory CD (especially Type II) is associated with increased mortality, primarily due to complications like EATL.
• Quality of Life:
  • Significant improvement in quality of life is seen with GFD adherence and resolution of symptoms.
  • However, the challenges of maintaining a strict GFD can impact social life and lead to dietary anxiety for some. Persistent symptoms (e.g., IBS-like) can also affect QoL.

Prevention

• Primary:
  • No proven methods to prevent the development of celiac disease in genetically susceptible individuals.
  • Previous recommendations on timing of gluten introduction (e.g., delaying, introducing while breastfeeding) have been largely disproven by large prospective studies (e.g., PreventCD, CELIPREV).
• Secondary:
  • Screening of At-Risk Groups: Proactive screening of first-degree relatives of CD patients (starting from age 2-3 years, or at diagnosis of other autoimmune diseases), individuals with Type 1 Diabetes, autoimmune thyroid disease, Down syndrome, Turner syndrome, and selective IgA deficiency.
• Tertiary:
  • Strict and lifelong Gluten-Free Diet: Essential for preventing the long-term complications of celiac disease, including nutritional deficiencies, osteoporosis, and the rare but serious risk of malignancy (EATL).

Special Populations

• Pediatric:
  • Presentation: Often classical malabsorption (chronic diarrhea, abdominal distension, weight loss, growth faltering, delayed puberty). Atypical presentations (fatigue, anemia, dental enamel defects, irritability) are also common.
  • Diagnosis: Serology (tTG-IgA, total IgA) remains first-line. ESPGHAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition) guidelines allow for a non-biopsy diagnosis in children and adolescents with symptoms suggestive of CD, tTG-IgA levels >10 times the upper limit of normal, and positive EMA-IgA in a second blood sample. HLA-DQ2/DQ8 testing is useful to exclude CD if negative.
  • Management: Strict GFD. Close monitoring of growth and development. Dietary education is crucial for parents and children.
• Geriatric:
  • Presentation: Often atypical, non-classical, and predominantly extra-intestinal symptoms (e.g., fatigue, anemia, osteoporosis, neurological symptoms). Diagnosis may be delayed.
  • Challenges: Polypharmacy, comorbidities, and potentially reduced adherence to GFD due to social or cognitive factors. Nutritional status (especially bone health) requires careful monitoring.
• Pregnancy:
  • Impact on Pregnancy: Untreated or poorly controlled CD can be associated with adverse pregnancy outcomes (e.g., recurrent miscarriages, low birth weight, preterm birth, infertility).
  • Management: Strict adherence to GFD is critical throughout pregnancy to optimize maternal health and fetal outcomes. Nutritional deficiencies (iron, folate, B12, vitamin D) should be aggressively monitored and corrected.
• Comorbidities:
  • Type 1 Diabetes Mellitus (T1DM): High co-occurrence (up to 10%). Screening for CD is recommended in all T1DM patients at diagnosis and periodically thereafter.
  • Autoimmune Thyroid Disease: Also a common comorbidity.
  • Selective IgA Deficiency: Screen with IgG-based tests.
  • Down Syndrome, Turner Syndrome, Williams Syndrome: Increased prevalence of CD.

Clinical Pearls

• Diagnostic:
  • "No Gluten, No Test": Emphasize to patients that they must be on a gluten-containing diet when undergoing serological testing and endoscopic biopsy. Stopping gluten before testing can lead to false-negative results, making diagnosis difficult. A gluten challenge (reintroduction) may be necessary but can cause significant symptoms.
  • Always check Total IgA: A normal tTG-IgA in an IgA deficient patient will be a false negative.
  • HLA-DQ2/DQ8 is a powerful rule-out: If negative, CD is virtually excluded. A positive test indicates genetic susceptibility but not active disease.
  • Consider biopsy even with negative serology: If clinical suspicion remains high and the patient is on a gluten-containing diet (e.g., IgA deficiency, potential non-celiac enteropathy).
• Treatment:
  • Dietitian is Key: A registered dietitian specialized in CD is invaluable for teaching practical GFD adherence, identifying hidden gluten, and managing nutritional challenges.
  • Lifelong Commitment: Patients need to understand that the GFD is a lifelong commitment, not a temporary diet.
  • Cross-contamination awareness: A major challenge for patients. Educate on safe food preparation, eating out, and shared kitchen spaces.
• Pitfalls:
  • Misdiagnosis: Attributing symptoms to IBS, lactose intolerance, or other conditions without considering CD.
  • Inadequate Biopsies: Insufficient number or incorrect location of biopsies (e.g., only taking from the duodenal bulb or stomach).
  • Starting GFD before diagnosis: Leads to diagnostic confusion and potentially unnecessary gluten challenge.
  • Missing IgA Deficiency: Leading to false negative serology.
  • Poor Adherence: A common reason for persistent symptoms and lack of mucosal healing.

Recent Updates

• Guidelines:
  • ESPGHAN (2020) and NASPGHAN (2019) guidelines for pediatric CD diagnosis increasingly support non-biopsy diagnosis in children with very high tTG-IgA levels (>10x ULN) and positive EMA.
  • ACG (American College of Gastroenterology, 2013) / AGA (American Gastroenterological Association, 2017) guidelines for adults reinforce the role of serology and biopsy.
• Evidence:
  • Ongoing research into non-dietary therapies (e.g., oral enzymes that degrade gluten, gluten-binding polymers, tight junction modulators, tTG inhibitors) to supplement or replace GFD, though none are currently approved for routine clinical use.
  • Better understanding of the extra-intestinal manifestations and their prevalence.
  • Increased awareness and diagnosis of "silent" and "atypical" forms of CD.
• Controversies:
  • Role of repeat biopsy for mucosal healing: While serology normalization often correlates with mucosal healing, some advocate for repeat biopsy (e.g., 2 years post-diagnosis) in adults to confirm healing, especially if symptoms persist or serology doesn't fully normalize, to reduce long-term complication risk.
  • Definition and management of non-responsive CD: Distinguishing between poor GFD adherence, refractory CD, and other concurrent conditions remains a challenge.
  • Utility of gluten challenge: When and how to perform a gluten challenge in patients who self-diagnosed or started GFD before proper testing.

Key References

• Husby, S., et al. (2020). ESPGHAN Clinical Guidelines: Diagnosis of Celiac Disease in Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition, 70(1), 141-155.
• Rubio-Tapia, A., et al. (2013). ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease. American Journal of Gastroenterology, 108(5), 656-676.
• Lebwohl, B., et al. (2015). Celiac Disease. The Lancet, 386(9993), 447-456. (Excellent comprehensive review).
• Green, P. H. R., & Cellier, C. (2007). Celiac Disease. New England Journal of Medicine, 357(17), 1731-1743.
• Kelly, C. P., et al. (2015). The Celiac Disease Clinical Guide (2nd Ed.). AGA Institute.
• Kagnoff, M. F. (2018). Celiac disease: Pathogenesis. UpToDate. Retrieved from www.uptodate.com
• Mayo Clinic (2023). Celiac disease. Mayo Clinic. Retrieved from www.mayoclinic.org/diseases-conditions/celiac-disease/symptoms-causes/syc-20352220